Loading...
•
Mar 31, 2022
SIGA Technologies Q1 2022 Earnings Report
SIGA Technologies' financial performance was marked by the first sale of IV TPOXX to the U.S. government and a new contract in the Asia Pacific region.
Key Takeaways
SIGA Technologies reported a revenue increase for the three months ended March 31, 2022, driven by the first sale of intravenous TPOXX to the U.S. government and a new international contract. The company also declared a special dividend of $0.45 per share.
Total revenues increased to $10.5 million compared to $4.8 million in the same period last year.
The first sale of intravenous (IV) TPOXX to the U.S. government was completed.
A new contract was secured with a jurisdiction in the Asia Pacific region for approximately $3 million of oral TPOXX.
The Board of Directors declared a special dividend of $0.45 per share.
SIGA Technologies
SIGA Technologies
SIGA Technologies Revenue by Segment
Revenue by Segment
Product sales & supportive services Revenue
CapyFin.comResearch and development Revenue
CapyFin.com Forward Guidance
SIGA Technologies did not provide specific forward guidance in this earnings report. The company's future performance is subject to various risks and uncertainties, including BARDA contract options, international market development, and the impact of COVID-19.
Positive Outlook
- EMA approval broadens market access
- New contract with Asia Pacific jurisdiction
- Increased oral TPOXX procurement contract with Canada
- Research collaboration with Bioarchitech
- First sale of IV TPOXX to the U.S. government
Challenges Ahead
- Risk that BARDA may not exercise all contract options
- Risk of not completing BARDA contracts on schedule
- Risk of BARDA contracts being modified or canceled
- Risk of international biodefense market not developing
- Risk of COVID-19 impacting SIGA's operations